Contineum Therapeutics, Inc. (CTNM) was recently elevated to a Zacks Rank #2 (Buy), reflecting analysts’ improved outlook on the company’s near-term earnings potential. Zacks highlights a positive earnings surprise history and an upward trend in consensus earnings forecasts over the past two quarters. The upgrade follows CTNM’s announcement of expanded commercial partnerships in gene therapy delivery, which analysts believe will drive revenue growth in 2026.

A consortium of ten Wall Street analysts has set an average price target implying a 91.49% upside for CTNM shares. This collective projection ranks among the highest upside estimates in the small-cap biotech sector. While price targets vary by firm, the median forecast sits 85% above current trading levels. Analysts cite accelerating enrollment in CTNM’s Phase 2 oncology trial as the primary catalyst for this bullish valuation consensus.

Over the past three months, consensus earnings-per-share estimates for CTNM’s fiscal 2026 have been revised upward by 12%, according to industry data. This positive revision trend stands in contrast to flat or downward adjustments seen in comparable biotechs. The revisions stem from stronger-than-expected preclinical data release in December and early feedback from key opinion leaders in the gene therapy field, bolstering expectations for improved profitability by late 2026.